Ra Pharmaceuticals 'pleased' with initial data from RA101495 program
"We are pleased with the initial data from the first two eculizumab-naive patients enrolled in our Phase 2 program evaluating RA101495 in PNH, which showed rapid declines in lactate dehydrogenase, near-complete inhibition of hemolytic activity, and no safety or tolerability concerns. The strength of these data enabled the opening of the eculizumab-switch cohort and generated strong interest from investigators and patients," said Ramin Farzaneh-Far, MD, Chief Medical Officer of Ra Pharma. "Recruitment has since progressed rapidly, with a total of 17 patients currently enrolled, 14 of whom are already receiving study drug. Enrollment targets in both the eculizumab-naive and eculizumab-switch cohorts have been met, and the first two patients receiving RA101495 have transitioned to a long-term extension study."